No items found.
Left chevron

Go Back

Pharmacology

Mineralocorticoid Receptor Antagonists: Pharmacology Made Easy & Clinically Relevant

Better care for heart failure, hypertension, and CKD starts with mastering the MRAs - finerenone, eplerenone, & spironolactone. Don’t just memorize; understand how they work & apply them in practice.

Video thumbnail

To view this video, please enable marketing cookies from Cookie Preferences in the footer.

Horizontal dot pattern

In this This Is Why with Dr. Busti pharmacology review, Dr. Busti unpacks the mechanisms, clinical relevance, and evolution of mineralocorticoid receptor antagonists (MRAs) or also referred to as aldosterone antagonists — a class that reshaped the management of heart failure, resistant hypertension, and cirrhosis. From the landmark RALES and EPHESUS trials to the emergence of selective agents like finerenone, he connects the evidence to the underlying physiology, explaining how MRAs influence cardiac remodeling, renal function, and survival outcomes.

Listeners will gain a clear understanding of spironolactone, eplerenone, and finerenone, how structural differences drive their selectivity and side effect profiles, and what to monitor to ensure safe, effective therapy. The goals = pharmacology made relevant and pharmacology made easy

Chapter Table of Contents

00:00:00 Introduction | Understanding MRAs and their clinical evolution
00:01:37 Why MRAs Matter | Mortality benefits in heart failure & hypertension
00:02:28 Drug Class Overview | Spironolactone · Eplerenone · Finerenone
00:03:13 Indications & Uses | Heart failure · CKD · Ascites · Hyperaldosteronism
00:06:27 Clinical Trial Evidence | RALES · EPHESUS · FIDELIO-DKD
00:10:32 Mechanism of Action | Blocking aldosterone & sodium-water retention
00:11:21 Renal Perfusion & Anatomy | How kidney blood flow impacts efficacy
00:15:30 The Nephron in Context | Where MRAs act in the distal nephron
00:39:18 Receptor Selectivity | Steroidal vs nonsteroidal binding differences
00:40:50 Pharmacokinetics | Absorption, distribution & CYP3A4 metabolism
00:42:30 Side Effects | Hyperkalemia, endocrine changes, dose considerations
00:48:20 Structural Chemistry | How design reduces side effects like gynecomastia
00:50:14 Drug Interactions | CYP3A4 inhibitors, ACEi/ARB & NSAID impacts
00:54:41 Monitoring & Labs | Potassium · Renal function · Blood pressure
00:56:40 Patient Counseling | Salt substitutes, polypharmacy & education
00:58:51 Clinical Pearls | Balancing risk and benefit in heart failure care
00:59:38 Closing Thoughts | Evidence meets understanding in MRA therapy

#MRAs #AldosteroneAntagonists #spironolactone #pharmacology #pharmacologymadeeasy

Disclaimer: This content is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard in this content.

This is why - membership

More than just access—it’s where understanding deepens.

Create a free account or log in to gain access to this content!

Dot pattern graphic

Dive Deeper

Bonus Video (ad free)

Deep Dive video thumbnail

To view this video, please enable marketing cookies.

Downloads

Mineralocorticoid Receptor Antagonist Tables

Dive Deeper

Bonus Video

Downloads

Mineralocorticoid Receptor Antagonist Tables